GAS5 and type 2 diabetes mellitus: Distinct studies demonstrate elevated circulating GAS5 levels in CHD patients [26], whereas serum GAS5 is significantly reduced in type 2 diabetes mellitus (T2DM) patients, with parallel downregulation observed in adipocytes from T2DM individuals [40].